We Believe Our Approach Has Created a Leading Pipeline of Multiple Drug and Development Candidates in Targeted Radiopharmaceutical Therapeutics
We have built a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs. We only file an IND and advance programs beyond IND enabling studies and into formal clinical development once we have conducted rigorous preclinical evaluation and early human imaging studies.
Agent: RYZ101 | Target: SSTR2 | IND Enabling | Phase 1 | Phase 2 | Phase 3 | GEP-NETs* RYZ101 vs Soc |
|---|---|---|---|---|---|
ES-SLC RYZ101 + Soc | |||||
HR+/HER2-BC RYZ101-201 | |||||
Agent: RYZ801/RYZ811 | Target: GPC3 | IND Enabling | Phase 1 | Phase 2 | Phase 3 | HCC RYZ811 / RYZ801 |
Agent: Pre-clinical | Target: Target | IND Enabling | Phase 1 | Phase 2 | Phase 3 | Pre-clinical ccRCC CAIX-targeted small molecule |
| Agent: RYZ101 Target: SSTR2 |
|||
|---|---|---|---|
| IND Enabling | Phase 1 | Phase 2 | Phase 3 | Action-1 GEP-NETs* RYZ101 vs Soc |
| RYZ101-101 ES-SLC RYZ101 + Soc | |||
| Tracy-1 HR+/HER2-BC RYZ101-201 | |||
| Agent: RYZ801/RYZ811 Target: GPC3 |
|||
| IND Enabling | Phase 1 | Phase 2 | Phase 3 | RYZ801-101 HCC RYZ811 / RYZ801 |
| Agent: Pre-clinical Target: Target |
|||
| IND Enabling | Phase 1 | Phase 2 | Phase 3 | Pre-clinical ccRCC CAIX-targeted small molecule |
*GEP-NETs expressing SSTR2 who are refractory to Lu177 SSA treatment.
